

# William Busse

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8421906/william-busse-publications-by-year.pdf>

**Version:** 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

233  
papers

28,036  
citations

78  
h-index

165  
g-index

261  
ext. papers

32,611  
ext. citations

8.5  
avg, IF

7  
L-index

#	Paper	IF	Citations
233	Holy Grail: the journey towards disease modification in asthma.. <i>European Respiratory Review</i> , <b>2022</b> , 31,	9.8	1
232	Uncontrolled asthma across GINA treatment steps 2 - 5 in a large US patient cohort. <i>Journal of Asthma</i> , <b>2021</b> , 1-13	1.9	3
231	Development of nasal allergen challenge with cockroach in children with asthma. <i>Pediatric Allergy and Immunology</i> , <b>2021</b> , 32, 971-979	4.2	0
230	Inducible expression quantitative trait locus analysis of the MUC5AC gene in asthma in urban populations of children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 1505-1514	11.5	1
229	Cockroach-induced IL9, IL13, and IL31 expression and the development of allergic asthma in urban children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1974-1977.e3	11.5	1
228	What is the contribution of IgE to nasal polyposis?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 147, 1997-2008	11.5	9
227	Prevention and Treatment of Asthma Exacerbations in Adults. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 2578-2586	5.4	0
226	Benralizumab for adolescent patients with severe, eosinophilic asthma: Safety and efficacy after 3 years of treatment. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> , 148, 266-271.e2	11.5	7
225	Possible Protective Effect of Omalizumab on Lung Function Decline in Patients Experiencing Asthma Exacerbations. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1201-1211	5.4	2
224	The Relationship of Asthma Biologics to Remission for Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2021</b> , 9, 1090-1098	5.4	6
223	Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma. <i>Journal of Asthma</i> , <b>2021</b> , 58, 514-522	1.9	17
222	Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	19
221	Impact of baseline patient characteristics on dupilumab efficacy in type 2 asthma. <i>European Respiratory Journal</i> , <b>2021</b> , 58,	13.6	2
220	Benefits of Airway Androgen Receptor Expression in Human Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2021</b> , 204, 285-293	10.2	10
219	Neuroimaging and biomarker evidence of neurodegeneration in asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2021</b> ,	11.5	2
218	Baseline FeNO as a prognostic biomarker for subsequent severe asthma exacerbations in patients with uncontrolled, moderate-to-severe asthma receiving placebo in the LIBERTY ASTHMA QUEST study: a post-hoc analysis. <i>Lancet Respiratory Medicine</i> , <b>2021</b> , 9, 1165-1173	35.1	16
217	Expression quantitative trait locus fine mapping of the 17q12-21 asthma locus in African American children: a genetic association and gene expression study. <i>Lancet Respiratory Medicine</i> , <b>2020</b> , 8, 482-492	25.1	20

216	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 125, 565-576.e1	3.2	17
215	Treatment Benefit with Omalizumab in Children by Indicators of Asthma Severity. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 2673-2680.e3	5.4	7
214	Aeroallergen Sensitization, Serum IgE, and Eosinophilia as Predictors of Response to Omalizumab Therapy During the Fall Season Among Children with Persistent Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 3021-3028.e2	5.4	5
213	genotype identifies glucocorticoid responsiveness in severe asthma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2020</b> , 117, 2187-2193	11.5	15
212	How to compare the efficacy of biologic agents in asthma. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 125, 137-149	3.2	3
211	Serum IL-6: A biomarker in childhood asthma?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1701-1704.e3	11.5	3
210	Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 203-206.e3	11.5	285
209	An expert consensus framework for asthma remission as a treatment goal. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 757-765	11.5	31
208	Effect of omalizumab on lung function and eosinophil levels in adolescents with moderate-to-severe allergic asthma. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2020</b> , 124, 190-196	3.2	21
207	In lasting tribute: Charles E. Reed, March 13, 1922, to July 24, 2020. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 984-986	11.5	0
206	Reply. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 146, 1214-1215	11.5	
205	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2020</b> , 8, 527-539.e9	5.4	20
204	Investigation of the relationship between IL-6 and type 2 biomarkers in patients with severe asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 430-433	11.5	22
203	Type 2 immunity in the skin and lungs. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 75, 1582-1605	9.3	111
202	BAL Cell Gene Expression in Severe Asthma Reveals Mechanisms of Severe Disease and Influences of Medications. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2019</b> , 200, 837-856	10.2	20
201	Global Initiative for Asthma 2016-derived asthma control with fluticasone propionate and salmeterol: A Gaining Optimal Asthma Control (GOAL) study reanalysis. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2019</b> , 123, 57-63.e2	3.2	6
200	Transcriptome networks identify mechanisms of viral and nonviral asthma exacerbations in children. <i>Nature Immunology</i> , <b>2019</b> , 20, 637-651	19.1	52
199	Biological treatments for severe asthma: A major advance in asthma care. <i>Allergology International</i> , <b>2019</b> , 68, 158-166	4.4	77

198	Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2019</b> , 7, 156-164.e1	5.4	97
197	Expression of corticosteroid-regulated genes by PBMCs in children with asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 940-947.e6	11.5	4
196	A computerized decision support tool to implement asthma guidelines for children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1760-1768	11.5	8
195	Reply. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1267-1268	11.5	
194	Two-Year Integrated Efficacy And Safety Analysis Of Benralizumab In Severe Asthma. <i>Journal of Asthma and Allergy</i> , <b>2019</b> , 12, 401-413	3.1	15
193	Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma. <i>European Respiratory Journal</i> , <b>2019</b> , 53,	13.6	30
192	Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. <i>Lancet Respiratory Medicine</i> , <b>2019</b> , 7, 46-59	35.1	138
191	Rhinitis in children and adolescents with asthma: Ubiquitous, difficult to control, and associated with asthma outcomes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 1003-1011.e10	11.5	30
190	Anti-IL-5 treatments in patients with severe asthma by blood eosinophil thresholds: Indirect treatment comparison. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 143, 190-200.e20	11.5	127
189	Biologic Therapy and Asthma. <i>Seminars in Respiratory and Critical Care Medicine</i> , <b>2018</b> , 39, 100-114	3.9	11
188	Obstruction phenotype as a predictor of asthma severity and instability in children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1090-1099.e4	11.5	20
187	Liberty Asthma QUEST: Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate Dupilumab Efficacy/Safety in Patients with Uncontrolled, Moderate-to-Severe Asthma. <i>Advances in Therapy</i> , <b>2018</b> , 35, 737-748	4.1	77
186	Allergen-induced activation of natural killer cells represents an early-life immune response in the development of allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1856-1866	11.5	21
185	Controversies and opportunities in severe asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2018</b> , 24, 83-93		9
184	Enhanced plasmacytoid dendritic cell antiviral responses after omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 1735-1743.e9	11.5	93
183	Biological treatments for severe asthma: where do we stand?. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2018</b> , 18, 509-518	3.3	17
182	Safety Trials of Long-Acting $\beta$ Agonists. <i>New England Journal of Medicine</i> , <b>2018</b> , 379, 1482	59.2	
181	Tiotropium add-on to inhaled corticosteroids versus addition of long-acting $\beta$ agonists for adults with asthma. <i>Respiratory Medicine</i> , <b>2018</b> , 143, 82-90	4.6	15

180	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2486-2496	59.2	763
179	Combined Analysis of Asthma Safety Trials of Long-Acting $\beta$ Agonists. <i>New England Journal of Medicine</i> , <b>2018</b> , 378, 2497-2505	59.2	50
178	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, S1-S14	5.4	45
177	Can we predict fall asthma exacerbations? Validation of the seasonal asthma exacerbation index. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 1130-1137.e5	11.5	28
176	Biologics for asthma in patients with asthma-COPD overlap. <i>Lancet Respiratory Medicine</i> , <b>2017</b> , 5, 175-177	35.1	4
175	A Deep Dive into Asthma Transcriptomics. Lessons from U-BIOPRED. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1279-1280	10.2	8
174	Omalizumab in children with uncontrolled allergic asthma: Review of clinical trial and real-world experience. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1431-1444	11.5	93
173	Should recommendations about starting inhaled corticosteroid treatment for mild asthma be based on symptom frequency: a post-hoc efficacy analysis of the START study. <i>Lancet, The</i> , <b>2017</b> , 389, 157-166	40	100
172	Effects of Omalizumab on Rhinovirus Infections, Illnesses, and Exacerbations of Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 196, 985-992	10.2	135
171	Reply. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1408-1409	11.5	
170	Gene Expression Correlated with Severe Asthma Characteristics Reveals Heterogeneous Mechanisms of Severe Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2017</b> , 195, 1449-1463	10.2	87
169	Baseline asthma burden, comorbidities, and biomarkers in omalizumab-treated patients in PROSPERO. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2017</b> , 119, 524-532.e2	3.2	22
168	New and Anticipated Therapies for Severe Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, S15-S24	5.4	21
167	Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 918-927	5.4	146
166	A role for neutrophils in asthma exacerbations. <i>Nature Medicine</i> , <b>2017</b> , 23, 658-659	50.5	18
165	Asthma control using fluticasone propionate/salmeterol in Asian and non-Asian populations: a post hoc analysis of the GOAL study. <i>BMC Pulmonary Medicine</i> , <b>2017</b> , 17, 75	3.5	0
164	A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 140, 162-169.e2	11.5	120
163	The nasal methylome and childhood atopic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1478-1488	11.5	91

162	Anaphylaxis Conundrum: A Trojan Horse Phenomenon. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 325-329	5.4	6
161	Dust Mite-Induced Perennial Allergic Rhinitis in Pediatric Patients and Sublingual Immunotherapy. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2017</b> , 5, 46-51	5.4	7
160	An Integrated Analysis of Fluticasone Furoate/Vilanterol (FF/VI) Versus FF Safety Data Across Phase II and III Asthma Studies. <i>Pulmonary Therapy</i> , <b>2016</b> , 2, 91-114	3	1
159	Integrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma. <i>Respiratory Research</i> , <b>2016</b> , 17, 157	7.3	7
158	Expression of asthma susceptibility genes in bronchial epithelial cells and bronchial alveolar lavage in the Severe Asthma Research Program (SARP) cohort. <i>Journal of Asthma</i> , <b>2016</b> , 53, 775-82	1.9	15
157	Efficacy and safety of ipratropium bromide/albuterol compared with albuterol in patients with moderate-to-severe asthma: a randomized controlled trial. <i>BMC Pulmonary Medicine</i> , <b>2016</b> , 16, 65	3.5	13
156	Reducing Exacerbations in the Inner City: Lessons from the Inner-City Asthma Consortium (ICAC). <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2016</b> , 4, 22-6	5.4	14
155	Airway factor XIII associates with type 2 inflammation and airway obstruction in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 767-73.e6	11.5	15
154	Long-acting muscarinic antagonists: a potential add-on therapy in the treatment of asthma?. <i>European Respiratory Review</i> , <b>2016</b> , 25, 54-64	9.8	28
153	IgE-mediated asthma: New revelations and future insights. <i>Respiratory Medicine</i> , <b>2016</b> , 112, 128-9	4.6	13
152	Safety and tolerability of once-daily tiotropium Respimat(®) as add-on to at least inhaled corticosteroids in adult patients with symptomatic asthma: A pooled safety analysis. <i>Respiratory Medicine</i> , <b>2016</b> , 118, 102-111	4.6	26
151	Mind-body interactions in the regulation of airway inflammation in asthma: A PET study of acute and chronic stress. <i>Brain, Behavior, and Immunity</i> , <b>2016</b> , 58, 18-30	16.6	39
150	Biomarkers in asthmatic patients: Has their time come to direct treatment?. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 137, 1317-24	11.5	68
149	Benralizumab, an anti-interleukin-5 receptor $\beta$ monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. <i>Lancet, The</i> , <b>2016</b> , 388, 2128-2141	40	738
148	Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1030-1041	11.5	69
147	Pathways through which asthma risk factors contribute to asthma severity in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1042-1050	11.5	54
146	Asthma phenotypes in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2016</b> , 138, 1016-1022	11.5	82
145	DNA methylation and childhood asthma in the inner city. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 69-80	11.5	157

144	Seasonal risk factors for asthma exacerbations among inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 135, 1465-73.e5	11.5	111
143	Biologics in asthma--the next step toward personalized treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 152-60; quiz 161	5.4	55
142	Roflumilast for asthma: Efficacy findings in placebo-controlled studies. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 35 Suppl, S20-7	3.5	30
141	Is It Asthma or Is It COPD: The Overlap Syndrome. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2015</b> , 3, 641-2; quiz 643	5.4	4
140	Roflumilast for asthma: Safety findings from a pooled analysis of ten clinical studies. <i>Pulmonary Pharmacology and Therapeutics</i> , <b>2015</b> , 35 Suppl, S28-34	3.5	11
139	Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 1476-1485	11.5	349
138	Discriminating sputum-eosinophilic asthma: Accuracy of cutoffs in blood eosinophil measurements versus a composite index, ELEN. <i>Journal of Allergy and Clinical Immunology</i> , <b>2015</b> , 136, 812-814.e2	11.5	23
137	Phenotype of asthmatics with increased airway S-nitrosoglutathione reductase activity. <i>European Respiratory Journal</i> , <b>2015</b> , 45, 87-97	13.6	20
136	Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF25-75), Independently of FEV1, in Adult Patients with Asthma. <i>PLoS ONE</i> , <b>2015</b> , 10, e0145476	3.7	35
135	Efficacy and safety of fluticasone furoate 100 µg once-daily in patients with persistent asthma: a 24-week placebo and active-controlled randomised trial. <i>Respiratory Medicine</i> , <b>2014</b> , 108, 41-9	4.6	31
134	Omalizumab in asthma: an update on recent developments. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2014</b> , 2, 525-36.e1	5.4	145
133	Longitudinal changes in airway remodeling and air trapping in severe asthma. <i>Academic Radiology</i> , <b>2014</b> , 21, 986-93	4.3	33
132	Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. <i>European Respiratory Journal</i> , <b>2014</b> , 43, 773-82	13.6	58
131	Benralizumab, an anti-interleukin 5 receptor $\beta$ monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study. <i>Lancet Respiratory Medicine</i> , <b>2014</b> , 2, 879-890	35.1	367
130	Efficacy and safety of fluticasone furoate 100 µg and 200 µg once daily in the treatment of moderate-severe asthma in adults and adolescents: a 24-week randomised study. <i>BMC Pulmonary Medicine</i> , <b>2014</b> , 14, 113	3.5	17
129	Efficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial. <i>Respiratory Research</i> , <b>2014</b> , 15, 88	7.3	17
128	Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids. <i>Journal of Negative Results in BioMedicine</i> , <b>2014</b> , 13, 9		15
127	Sputum neutrophil counts are associated with more severe asthma phenotypes using cluster analysis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 1557-63.e5	11.5	377

126	Characterization of factors associated with systemic corticosteroid use in severe asthma: data from the Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 915-8	11.5	25
125	Designing clinical trials to address the needs of childhood and adult asthma: the National Heart, Lung, and Blood Institute's AsthmaNet. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 34-8.e1	11.5	19
124	Reply: To PMID 23591271. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 1231	11.5	
123	Unsupervised phenotyping of Severe Asthma Research Program participants using expanded lung data. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 1280-8	11.5	193
122	Fluticasone furoate-vilanterol 100-25 mcg compared with fluticasone furoate 100 mcg in asthma: a randomized trial. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2014</b> , 2, 553-61	5.4	32
121	Effect of rare variants in ADRB2 on risk of severe exacerbations and symptom control during longacting β <sub>2</sub> agonist treatment in a multiethnic asthma population: a genetic study. <i>Lancet Respiratory Medicine</i> , <b>2014</b> , 2, 204-13	35.1	85
120	Effects of early-life exposure to allergens and bacteria on recurrent wheeze and atopy in urban children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 134, 593-601.e12	11.5	263
119	Executive Summary: NHLBI Workshop on the Primary Prevention of Chronic Lung Diseases. <i>Annals of the American Thoracic Society</i> , <b>2014</b> , 11 Suppl 3, S123-4	4.7	5
118	Once-daily fluticasone furoate (FF)/vilanterol reduces risk of severe exacerbations in asthma versus FF alone. <i>Thorax</i> , <b>2014</b> , 69, 312-9	7.3	60
117	Development of cockroach immunotherapy by the Inner-City Asthma Consortium. <i>Journal of Allergy and Clinical Immunology</i> , <b>2014</b> , 133, 846-52.e6	11.5	42
116	Management of Asthma in Adolescents and Adults <b>2014</b> , 902-922		
115	Severe asthma: an expanding and mounting clinical challenge. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2013</b> , 1, 110-21; quiz 122	5.4	31
114	Reassessment of omalizumab-dosing strategies and pharmacodynamics in inner-city children and adolescents. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , <b>2013</b> , 1, 163-71	5.4	49
113	Safety and efficacy of the prostaglandin D <sub>2</sub> receptor antagonist AMG 853 in asthmatic patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 339-45	11.5	76
112	Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 187, 804-11	10.2	609
111	High eosinophil count: a potential biomarker for assessing successful omalizumab treatment effects. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 485-6.e11	11.5	114
110	Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 132, 1086-1096.e5	11.5	320
109	The poorly explored impact of uncontrolled asthma. <i>Chest</i> , <b>2013</b> , 143, 511-523	5.3	63



108	Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 1294-302	10.2	422
107	Authors' reply to 'Safety and tolerability of fluticasone furoate/vilanterol'. <i>Thorax</i> , <b>2013</b> , 68, 1165-6	7.3	
106	Safety and tolerability of the novel inhaled corticosteroid fluticasone furoate in combination with the $\beta_2$ agonist vilanterol administered once daily for 52 weeks in patients $\geq 12$ years old with asthma: a randomised trial. <i>Thorax</i> , <b>2013</b> , 68, 513-20	7.3	59
105	Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: a randomized trial. <i>Chest</i> , <b>2013</b> , 144, 1222-1229	5.3	67
104	Characteristics of perimenstrual asthma and its relation to asthma severity and control: data from the Severe Asthma Research Program. <i>Chest</i> , <b>2013</b> , 143, 984-992	5.3	58
103	Randomized, Double-Blind, Placebo-controlled Study of Brodalumab, a Human AntiIL-17 Receptor Monoclonal Antibody, in Moderate to Severe Asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2013</b> , 188, 1294-1302	10.2	294
102	Dose effect of once-daily fluticasone furoate in persistent asthma: a randomized trial. <i>Respiratory Medicine</i> , <b>2012</b> , 106, 642-50	4.6	63
101	Allergen immunotherapy in allergic respiratory diseases: from mechanisms to meta-analyses. <i>Chest</i> , <b>2012</b> , 141, 1303-1314	5.3	34
100	Development and validation of the Composite Asthma Severity Index--an outcome measure for use in children and adolescents. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 694-701	11.5	87
99	Omalizumab and the risk of malignancy: results from a pooled analysis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2012</b> , 129, 983-9.e6	11.5	113
98	Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2012</b> , 109, 353-358.e4	3.2	41
97	Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2012</b> , 185, 356-62	10.2	198
96	Fluticasone furoate demonstrates efficacy in patients with asthma symptomatic on medium doses of inhaled corticosteroid therapy: an 8-week, randomised, placebo-controlled trial. <i>Thorax</i> , <b>2012</b> , 67, 35-41	7.3	60
95	24-h duration of the novel LABA vilanterol trifenate in asthma patients treated with inhaled corticosteroids. <i>European Respiratory Journal</i> , <b>2012</b> , 40, 570-9	13.6	57
94	What is the best pulmonary diagnostic approach for wheezing patients with normal spirometry?. <i>Respiratory Care</i> , <b>2012</b> , 57, 39-46; discussion 47-9	2.1	15
93	The brain and asthma: what are the linkages?. <i>Chemical Immunology and Allergy</i> , <b>2012</b> , 98, 14-31		18
92	Are there neurophenotypes for asthma? Functional brain imaging of the interaction between emotion and inflammation in asthma. <i>PLoS ONE</i> , <b>2012</b> , 7, e40921	3.7	59
91	Vaccination of patients with mild and severe asthma with a 2009 pandemic H1N1 influenza virus vaccine. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 130-7, 137.e1-3	11.5	28

90	House dust mite sublingual immunotherapy: results of a US trial. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 127, 974-81.e1-7	11.5	52
89	Asthma diagnosis and treatment: filling in the information gaps. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 740-50	11.5	39
88	Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 1005-15	59.2	647
87	Determinants of exhaled breath condensate pH in a large population with asthma. <i>Chest</i> , <b>2011</b> , 139, 328-336	5.3	56
86	Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 573-82	8	355
85	The role of allergy in disease. <i>Immunological Reviews</i> , <b>2011</b> , 242, 5-9	11.3	11
84	Fluticasone furoate: once-daily evening treatment versus twice-daily treatment in moderate asthma. <i>Respiratory Research</i> , <b>2011</b> , 12, 160	7.3	36
83	How cytokines co-occur across asthma patients: from bipartite network analysis to a molecular-based classification. <i>Journal of Biomedical Informatics</i> , <b>2011</b> , 44 Suppl 1, S24-S30	10.2	25
82	A randomized, controlled, phase 2 study of AMG 317, an IL-4Ralpha antagonist, in patients with asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 788-96	10.2	254
81	The relationship of airway hyperresponsiveness and airway inflammation: Airway hyperresponsiveness in asthma: its measurement and clinical significance. <i>Chest</i> , <b>2010</b> , 138, 4S-10S	5.3	116
80	Use of exhaled nitric oxide measurement to identify a reactive, at-risk phenotype among patients with asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 1033-41	10.2	215
79	Asthma: clinical expression and molecular mechanisms. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, S95-102	11.5	226
78	Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, 383-9	11.5	154
77	A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, 803-13	11.5	71
76	The National Institutes of Allergy and Infectious Diseases networks on asthma in inner-city children: an approach to improved care. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, 529-37; quiz 538-9	11.5	32
75	Safety profile, pharmacokinetics, and biologic activity of MEDI-563, an anti-IL-5 receptor alpha antibody, in a phase I study of subjects with mild asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 125, 1237-1244.e2	11.5	222
74	Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2010</b> , 181, 315-23	10.2	1427
73	Role of viral respiratory infections in asthma and asthma exacerbations. <i>Lancet, The</i> , <b>2010</b> , 376, 826-34	40	495

72	Biologic therapies for asthma. <i>Current Opinion in Pulmonary Medicine</i> , <b>2010</b> , 16, 19-24	3	10
71	Predicting intermediate phenotypes in asthma using bronchoalveolar lavage-derived cytokines. <i>Clinical and Translational Science</i> , <b>2010</b> , 3, 147-57	4.9	47
70	An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 180, 59-99	10.2	1304
69	Severe exacerbations and decline in lung function in asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2009</b> , 179, 19-24	10.2	275
68	The Urban Environment and Childhood Asthma (URECA) birth cohort study: design, methods, and study population. <i>BMC Pulmonary Medicine</i> , <b>2009</b> , 9, 17	3.5	65
67	Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. <i>Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 124, 245-52, 252.e1-3	11.5	69
66	Asthma morbidity among inner-city adolescents receiving guidelines-based therapy: role of predictors in the setting of high adherence. <i>Journal of Allergy and Clinical Immunology</i> , <b>2009</b> , 124, 213-21, 221.e1	11.5	24
65	Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage-derived cytokines. <i>Journal of Allergy and Clinical Immunology</i> , <b>2008</b> , 121, 30-37.e6	11.5	94
64	The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2008</b> , 121, 1167-74	11.5	104
63	Host immune responses to rhinovirus: mechanisms in asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2008</b> , 122, 671-682	11.5	75
62	Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. <i>Lancet, The</i> , <b>2008</b> , 372, 1065-72	4 <sup>0</sup>	34 <sup>1</sup>
61	Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2008</b> , 121, 1407-14, 1414.e1-6	11.5	38
60	Age-related changes in eosinophil function in human subjects. <i>Chest</i> , <b>2008</b> , 133, 412-9	5.3	116
59	Up-regulation and activation of eosinophil integrins in blood and airway after segmental lung antigen challenge. <i>Journal of Immunology</i> , <b>2008</b> , 180, 7622-35	5.3	49
58	Daclizumab improves asthma control in patients with moderate to severe persistent asthma: a randomized, controlled trial. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 178, 1002-8	10.2	122
57	The presence of rhinovirus in lower airways of patients with bronchial asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2008</b> , 177, 1082-9	10.2	98
56	Lung function in adults with stable but severe asthma: air trapping and incomplete reversal of obstruction with bronchodilation. <i>Journal of Applied Physiology</i> , <b>2008</b> , 104, 394-403	3.7	218
55	The Asthma Guidelines—What Do the Experts Teach Us? <b>2008</b> , 165-176		

54	Effect of omalizumab on the need for rescue systemic corticosteroid treatment in patients with moderate-to-severe persistent IgE-mediated allergic asthma: a pooled analysis. <i>Current Medical Research and Opinion</i> , <b>2007</b> , 23, 2379-86	2.5	41
53	Addressing issues of asthma in inner-city children. <i>Journal of Allergy and Clinical Immunology</i> , <b>2007</b> , 119, 43-9	11.5	69
52	Severe asthma: lessons from the Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , <b>2007</b> , 119, 14-21; quiz 22-3	11.5	183
51	Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. <i>Journal of Allergy and Clinical Immunology</i> , <b>2007</b> , 119, 405-13	11.5	709
50	A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2007</b> , 176, 1062-71	10.2	567
49	Generation of Th1 and Th2 chemokines by human eosinophils: evidence for a critical role of TNF-alpha. <i>Journal of Immunology</i> , <b>2007</b> , 179, 4840-8	5.3	85
48	The relationship of rhinovirus-associated asthma hospitalizations with inhaled corticosteroids and smoking. <i>Journal of Infectious Diseases</i> , <b>2006</b> , 193, 1536-43	7	62
47	Efficacy of montelukast during the allergy season in patients with chronic asthma and seasonal aeroallergen sensitivity. <i>Annals of Allergy, Asthma and Immunology</i> , <b>2006</b> , 96, 60-8	3.2	30
46	Asthma: diagnosis and management. <i>Medical Clinics of North America</i> , <b>2006</b> , 90, 39-60	7	16
45	Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>2006</b> , 117, 134-40	11.5	277
44	Cysteinyl Leukotrienes in Allergic Inflammation. <i>Chest</i> , <b>2005</b> , 127, 1312-1326	5.3	2
43	Neural circuitry underlying the interaction between emotion and asthma symptom exacerbation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 13319-24	11.5	165
42	Quantitative and qualitative analysis of rhinovirus infection in bronchial tissues. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2005</b> , 171, 645-51	10.2	182
41	Cysteinyl leukotrienes in allergic inflammation: strategic target for therapy. <i>Chest</i> , <b>2005</b> , 127, 1312-26	5.3	131
40	Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 583-93	10.2	517
39	Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma Control study. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 836-44	10.2	1250
38	Future research directions in asthma: an NHLBI Working Group report. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2004</b> , 170, 683-90	10.2	61
37	Preliminary safety and efficacy of daclizumab in the treatment of patients with moderate to severe chronic persistent asthma*1. <i>Journal of Allergy and Clinical Immunology</i> , <b>2004</b> , 113, S286-S287	11.5	8

36	Efficacy, tolerability, and effect on asthma-related quality of life of formoterol bid via multidose dry powder inhaler and albuterol QID via metered dose inhaler in patients with persistent asthma: a multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel-group study. <i>Clinical Therapeutics</i> , <b>2004</b> , 26, 1587-98	3.5	17
35	Is the eosinophil a "Humpty Dumpty" cell in asthma?. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 167, 102-3	10.2	12
34	Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2003</b> , 168, 1091-4	10.2	94
33	Steroid-sparing effects of fluticasone propionate 100 microg and salmeterol 50 microg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 microg administered twice daily. <i>Journal of Allergy and Clinical Immunology</i> , <b>2003</b> , 111, 57-65	11.5	69
32	Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. <i>Lancet, The</i> , <b>2003</b> , 361, 1071-6	40	566
31	Relationship of viral infections to wheezing illnesses and asthma. <i>Nature Reviews Immunology</i> , <b>2002</b> , 2, 132-8	36.5	102
30	School examinations enhance airway inflammation to antigen challenge. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>2002</b> , 165, 1062-7	10.2	229
29	Decreased expression of membrane IL-5 receptor alpha on human eosinophils: I. Loss of membrane IL-5 receptor alpha on airway eosinophils and increased soluble IL-5 receptor alpha in the airway after allergen challenge. <i>Journal of Immunology</i> , <b>2002</b> , 169, 6452-8	5.3	154
28	The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design. <i>Contemporary Clinical Trials</i> , <b>2001</b> , 22, 405-19		26
27	Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2001</b> , 108, 184-90	11.5	970
26	Asthma. <i>New England Journal of Medicine</i> , <b>2001</b> , 344, 350-62	59.2	1541
25	Anti-immunoglobulin E for the treatment of allergic disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2001</b> , 1, 105-108	3.3	9
24	Fluticasone propionate compared with zafirlukast in controlling persistent asthma: a randomized double-blind, placebo-controlled trial. <i>Journal of Family Practice</i> , <b>2001</b> , 50, 595-602	0.2	32
23	Anti-immunoglobulin E for the treatment of allergic disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , <b>2001</b> , 1, 105-8	3.3	3
22	Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. <i>Journal of Allergy and Clinical Immunology</i> , <b>2000</b> , 105, 692-8	11.5	100
21	The effect of an experimental rhinovirus 16 infection on bronchial lavage neutrophils. <i>Journal of Allergy and Clinical Immunology</i> , <b>2000</b> , 105, 1169-77	11.5	105
20	The role of viral infections in the natural history of asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>2000</b> , 106, 201-12	11.5	251
19	Determinants of risk factors for asthma. <i>Canadian Respiratory Journal</i> , <b>1999</b> , 6, 97-101	2.1	3

18	Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. <i>Journal of Allergy and Clinical Immunology</i> , <b>1998</b> , 101, 457-63	11.5	157
17	Results of the first U.S. double-blind, placebo-controlled, multicenter clinical study in asthma with pranlukast, a novel leukotriene receptor antagonist. <i>Journal of Asthma</i> , <b>1997</b> , 34, 321-8	1.9	70
16	Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>1997</b> , 100, 110-21	11.5	287
15	The role of respiratory viruses in asthma. <i>Novartis Foundation Symposium</i> , <b>1997</b> , 206, 208-13; discussion 213-9		15
14	Ragweed immunotherapy in adult asthma. <i>New England Journal of Medicine</i> , <b>1996</b> , 334, 501-6	59.2	182
13	A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial Comparing the Efficacy and Tolerability of Levocabastine-Oxymetazoline Nasal Spray with Levocabastine and Oxymetazoline Alone in the Symptomatic Treatment of Seasonal Allergic Rhinitis. <i>American Journal of Rhinology &amp; Allergy</i> , <b>1996</b> , 10, 107-112		1
12	Childhood- versus adult-onset asthma. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1995</b> , 151, 1635-9	10.2	67
11	Corticosteroids in the Treatment of Asthma. <i>BioDrugs</i> , <b>1995</b> , 4, 16-48		10
10	Treatment regimen and side effects of treatment measures. <i>American Journal of Respiratory and Critical Care Medicine</i> , <b>1994</b> , 149, S44-50; discussion S51-3	10.2	14
9	Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. <i>The American Review of Respiratory Disease</i> , <b>1991</b> , 144, 1274-81		265
8	In vitro incubation with influenza virus primes human polymorphonuclear leukocyte generation of superoxide. <i>American Journal of Respiratory Cell and Molecular Biology</i> , <b>1991</b> , 4, 347-54	5.7	21
7	The effect of azelastine on neutrophil and eosinophil generation of superoxide. <i>Journal of Allergy and Clinical Immunology</i> , <b>1989</b> , 83, 400-5	11.5	65
6	Effect of nedocromil sodium on the beta-adrenergic response of human polymorphonuclear leucocytes. <i>Drugs</i> , <b>1989</b> , 37 Suppl 1, 26-31; discussion 69-77	12.1	4
5	New directions and dimensions in the treatment of allergic rhinitis. <i>Journal of Allergy and Clinical Immunology</i> , <b>1988</b> , 82, 890-900	11.5	27
4	Combination low-dose metaproterenol-theophylline therapy in asthma. <i>Journal of Asthma</i> , <b>1983</b> , 20, 85-91	1.9	
3	Effect of Bordetella pertussis vaccination in mice and the isolated tracheal response to isoprenaline. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , <b>1980</b> , 35, 291-6	9.3	13
2	Histamine inhibition of neutrophil lysosomal enzyme release: an H2 histamine receptor response. <i>Science</i> , <b>1976</b> , 194, 737-8	33.3	78
1	Novel Biologicals Alone and in Combination in Asthma and Allergy 203-231		

